![]() |
市場調查報告書
商品編碼
1374432
全球玻璃化冷凍市場規模、佔有率、產業趨勢分析報告:2023-2030年按檢體、最終用途和地區分類的展望和預測Global Vitrification Market Size, Share & Industry Trends Analysis Report By Specimen (Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm), By End-use, By Regional Outlook and Forecast, 2023 - 2030 |
預計到2030年,玻璃化冷凍市場規模將達到 241 億美元,預測期內年複合成長率為 17.2%。
然而,有些人不喜歡人工創造生命的想法,如果任其自然發展就不可能存在。還有一種觀點認為應該把它留給「自然選擇」。一夫一妻制婚姻制度和人類生命的尊嚴都受到體外受精的影響。受精兒童也會出現身分問題。即使在人類生命的最初階段,從受孕開始,它就具有巨大的意義。可能影響社會和醫療保健專業人員的法律問題包括醫療事故指控,未成年患者的知情同意以及法定監護權。這些有關體外受精和生育力保存的倫理和技術問題可能會阻礙市場擴張。
此外,COVID-19 大流行對全球經濟產生了重大影響,醫療保健產業也未能倖免。疫情對市場產生了負面影響。國際生育協會建議,在世界衛生組織(WHO)COVID-19 大流行期間,除必要的醫學生育力保存外,不要繼續進行 IVF 治療。然而,隨著 COVID-19 限制的放鬆,IVF 診所和其他醫療機構可以在採取預防措施的情況下重新開放,例如配備足夠的工作人員並遵循適當的安全協議。這些因素都有助於市場在疫情後的早期復甦。
展望檢體
依檢體,市場分為卵子、胚胎和精子。2022年,胚胎細分市場在市場中獲得了可觀的收益佔有率。額外的胚胎被玻璃化冷凍保存。體外受精從業者將較少的新鮮胚胎傳輸到子宮中,以減少多胎妊娠的機會。如果第一個週期失敗,可以進行冷凍胚胎移植,而不是再次經歷卵巢刺激和取卵的不便。
卵子展望
卵子區隔進一步細分為設備和套件及消耗品。2022年,套件和消耗品部門在市場上獲得了可觀的收益佔有率。卵子玻璃化冷凍在生育力保存和輔助生殖技術中的成功取決於所用材料和程序的品質。玻璃化冷凍套件和消耗品可確保卵子保存時具有高活力和發育潛力,對該技術的整體成功率做出重大貢獻。
胚胎展望
胚胎區隔進一步分為設備、套件和消耗品。在2022年的市場中,設備細分市場佔據了最大的收益佔有率。玻璃化冷凍裝置,如吸管、小瓶或特殊容器,可作為胚胎的保護罩。它們在玻璃化冷凍過程中安全地容納胚胎,同時防止直接暴露於冷凍保護劑溶液並最大限度地減少物理損壞的風險。該裝置設計用於容納特定體積的玻璃化冷凍溶液和胚胎。
最終用途展望
根據最終用途,市場分為 IVF 診所和生物庫。2022年,IVF診所部門佔據市場最大的收益佔有率。越來越多的 IVF 診所提供玻璃化冷凍和其他 ART 服務,這可能會帶來可觀的收益佔有率。此外,該診所還提供精子、卵子和卵子儲存等服務,預計將增加診所的收入佔有率。玻璃化冷凍技術在體外受精的進展率以及冷凍卵子和胚胎的週期數方面顯著改善了生殖醫療環境。
區域展望
依地區分類,對北美、歐洲、亞太地區和拉丁美洲地區市場進行了分析。2022年,歐洲地區佔據最大的收益佔有率,引領市場。法國、西班牙、英國、英國和義大利等新興經濟體對此負有責任。由於這些國家基礎設施發達,預計該地區的低溫保存技術將大幅增加。此外,在英國和德國等國家,生物技術部門的擴張以及對輔助生殖技術市場開拓的財政支持促進市場成長。不孕症的高發生率和女性對卵子保存的興趣日益濃厚是該地區發展的主要驅動力。
The Global Vitrification Market size is expected to reach $24.1 billion by 2030, rising at a market growth of 17.2% CAGR during the forecast period.
Male fertility preservation and sperm cryopreservation are both crucial components of ART. It can help individuals with azoospermia or oligozoospermia avoid recurrent biopsies. Thus, the sperm segment will capture 1/5th share in the revenue by the year 2030. Before having chemotherapy or radiation therapy, cancer patients can also use this procedure to maintain their fertility. The standard freezing approach can achieve an adequate survival rate since mature sperm have a significant number and little volume and also tolerate freezing temperatures well. Some of the factors impacting the market are growing demand for organ transplants, rising percentage of first-time mothers at an older median age and ethical, and technical issues with IVF and fertility preservation.
Various reasons, such as pointless injury, poisoning, blood loss, drug abuse, etc., can cause organ failure. The rising incidence of renal disease, excessive alcohol use, and poor diet have pushed the growth of organ transplantation. Growing global organ donation also influences people's attitudes toward organ transplantation. By transforming them into a glass-like condition, vitrification enables the conservation of organs at extremely low temperatures (-196°C or -320°F). This makes it possible to store organs for a long time-possibly from hours to days-without any actual degradation. Additionally, over time, there has been a sharp increase in the median age of first-time mothers globally. More effective contraceptive methods, later marriages, and an increase in women prioritizing their careers over having children are the leading causes of this trend. Because of this, it is projected that as the average age of first-time mothers increases, more women will experience trouble conceiving naturally. More women are being forced to seek IVF treatments in this situation. The market is, therefore, anticipated to grow along with the rise in demand for organ transplants.
However, some individuals dislike the idea of artificially created life that couldn't exist if nature were left to itself. Another argument they can raise is that "natural selection" should be allowed to carry out its task. The institution of monogamous marriage and the sanctity of human life are both affected by in vitro fertilization. For the children who are conceived, it also raises issues with identity. Even in its earliest phases, starting with conception, human life has immense significance. Legal issues that could affect society and healthcare professionals include allegations of medical malpractice, informed consent from patients who are minors, and legal parentage. These ethical and technical issues with IVF and fertility preservation may hinder the market's expansion.
Additionally, the COVID-19 pandemic had a significant effect on the global economy; the healthcare industry was not exempted from this. The pandemic had a negative impact on the market. International fertility associations advised against continuing IVF therapy during the World Health Organization's (WHO) COVID-19 pandemic, except for necessary medical fertility preservation. However, the relaxation of COVID-19 limitations allowed IVF clinics and other healthcare facilities to reopen with precautions like ensuring adequate staff and adhering to appropriate safety procedures. In light of these elements, these factors aided in the market's quick recovery in the post-pandemic era.
Specimen Outlook
On the basis of specimen, the market is segmented into oocytes, embryos, and sperm. In 2022, the embryo segment acquired a substantial revenue share in the market. Extra embryos are vitrified to preserve them. IVF practitioners transfer fewer fresh embryos into the uterus to reduce the chance of multiple pregnancies. A frozen embryo transfer may be performed if the first cycle is unsuccessful rather than going through the inconveniences of ovarian stimulation and egg retrieval again.
Oocytes Outlook
The oocytes segment is further subdivided into devices and kits & consumables. The kits and consumables segment procured a significant revenue share in the market in 2022. The success of oocyte vitrification in fertility preservation and ART depends on the quality of the materials and procedures used. Vitrification kits and consumables contribute significantly to the overall success rate of the technique, ensuring that oocytes are preserved with high viability and developmental potential.
Embryo Outlook
The embryo segment is further bifurcated into devices and kits & consumables. The devices segment acquired the largest revenue share in the market in 2022. Vitrification devices, such as straws, vials, or specialized containers, serve as protective enclosures for embryos. They keep embryos securely contained during the vitrification process, preventing direct exposure to cryoprotectant solutions and minimizing the risk of physical damage. Devices are engineered to hold specific volumes of vitrification solutions and embryos.
End Use Outlook
Based on end-use, the market is fragmented into IVF clinics and biobanks. In 2022, the IVF clinics segment witnessed the largest revenue share in the market. The significant revenue share may result from the growing number of IVF clinics that provide vitrification and other ART services. Furthermore, the clinics are providing services like sperm, egg, and oocyte storage, which is anticipated to increase the income share of clinics. Regarding the IVF progress rate and the number of freezing cycles for oocytes and embryos, the vitrification technique considerably enhances the reproductive health environment.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Europe region led the market by generating the largest revenue share. The existence of developed economies like those of France, Spain, Germany, the UK, and Italy is responsible for this. Because of the developed infrastructure in these nations, cryopreservation techniques are expected to increase dramatically in the region. Furthermore, the biotechnology sector's expansion and financial support for the development of assisted reproductive technologies in nations like the UK and Germany contribute to market growth. The high incidence of infertility and rising interest among women in egg preservation are the main drivers of regional development.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitub GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech
Market Segments covered in the Report:
By Specimen
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research